Stouch Cheryl Ann 4

What Happened Cheryl Ann Stouch, EVP and Chief Information Officer of Keenova Therapeutics plc, received a grant of 15,936 restricted stock units (RSUs) on February 25, 2026. The RSUs were granted at $0.00 (no cash purchase) and are derivative awards that will convert to ordinary shares on a one-for-one basis upon vesting. The filing reflects an inclusion of 1,719 additional RSUs that resulted from an adjustment related to the separation of Par Health, Inc.

Key Details

• Transaction date: 2026-02-25 (Form 4 filed 2026-02-26). Transaction code: A (award/grant).
• Grant size and price: 15,936 RSUs granted at $0.00 each (total reported value $0).
• Vesting: RSUs will vest ratably in three annual installments beginning Feb 25, 2027 (i.e., on each of the first three anniversaries of Feb 25, 2027).
• Adjustment: 1,719 of the RSUs reflect an adjustment from the Par Health separation on Nov 10, 2025.
• Shares owned after the transaction: not specified in the filing.
• Regulatory note: The Form 4 includes a remark that it constitutes notice to the issuer under Part V of the Companies Act 2014.

Context RSUs are compensation awards, not open-market purchases or sales; they do not represent immediately tradable shares until they vest and are settled. This grant is a routine equity compensation event for an executive and should be viewed as such—informative about company pay practices but not a direct market buy/sell signal. The filing appears timely (filed the day after the reported grant) and simply documents the grant and the vesting/adjustment details.